Sugi Predict

Sugi Predict / Compounds / SCHEMBL2744934

SCHEMBL2744934

SCHEMBL2744934

COc1cc2c(Oc3ccc(N)cc3F)ncnc2cc1OCC1CCNCC1

nearest known ligand 0.57

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ EGFR P00533 9/20 0.57
▸ KDR P35968 9/20 0.57
▸ FGFR1 P11362 5/20 0.57
▸ FLT1 P17948 5/20 0.57
▸ FLT4 P35916 5/20 0.57
▸ TRPA1 O75762 1/20 0.55
▸ AXL P30530 2/20 0.50
▸ TYRO3 Q06418 1/20 0.50
▸ MERTK Q12866 1/20 0.50
▸ RAF1 P04049 1/20 0.49
▸ KIT P10721 2/20 0.48
▸ MET P08581 2/20 0.47
▸ ERBB2 P04626 1/20 0.45
▸ EPHA2 P29317 1/20 0.45
▸ EPHB4 P54760 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5571167 0.96 TRPA1 (0.57) EGFRKDRFGFR1FLT1FLT4
SCHEMBL20216698 0.90 KDR (0.70) EGFRKDRFGFR1FLT1FLT4
SCHEMBL17378104 0.87 TRPA1 (0.53) EGFRKDRFGFR1FLT1FLT4
SCHEMBL2744533 0.87 MET (0.60) EGFRKDRFGFR1FLT1FLT4
SCHEMBL2744926 0.87 KDR (0.53) EGFRKDRFGFR1FLT1FLT4
SCHEMBL5143476 0.85 EGFR (0.56) EGFRKDRFGFR1FLT1FLT4
SCHEMBL13680219 0.85 RAF1 (0.60) EGFRKDRFGFR1FLT1FLT4
SCHEMBL5571100 0.84 MET (0.57) EGFRKDRFGFR1FLT1FLT4
SCHEMBL5824789 0.84 TRPA1 (0.76) EGFRKDRTRPA1AXLKIT
SCHEMBL4398541 0.83 KDR (0.57) EGFRKDRFGFR1FLT1FLT4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3329918-B1 C-MET MODULATORS AND METHODS OF USE EXELIXIS INC (US) 2022-05-25 — — EP disclosed
US-11124482-B2 C-met modulators and methods of use EXELIXIS, INC. (US) 2021-09-21 — — US disclosed
US-20210253530-A9 C-MET MODULATORS AND METHODS OF USE EXELIXIS, INC. 2021-08-19 — — US disclosed
US-20200331860-A1 C-Met Modulators and Methods of Use EXELIXIS INC (US) 2020-10-22 — — US disclosed
EP-3329918-A2 C-MET MODULATORS AND METHODS OF USE Exelixis, Inc. (US) 2018-06-06 — — EP disclosed
US-20170355678-A1 C-Met Modulators and Methods of Use EXELIXIS INC (US) 2017-12-14 — — US disclosed
EP-2409704-B1 c-Met modulators and methods of use EXELIXIS INC (US) 2017-09-20 — — EP disclosed
US-20160185725-A1 c-Met Modulators and Method of Use EXELIXIS, INC. 2016-06-30 — — US disclosed
US-9174947-B2 c-Met modulators and methods of use Exelixus, Inc. (US) 2015-11-03 — — US disclosed
US-20140155396-A1 C-Met Modulators and Method of Use EXELIXIS, INC. 2014-06-05 — — US disclosed
EP-2213661-A1 c-Met Modulators and Methods of Use Exelixis Inc. (US) 2010-08-04 — — EP disclosed
EP-2210607-A1 N-[3-fluoro-4-({6-(methyloxy)-7-[(3-piperidin-1-ylpropyl)oxy]quinolin-4-yl}oxy)phenyl]-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide for the treatment of cancer Exelixis Inc. (US) 2010-07-28 — — EP disclosed
US-7579473-B2 N-(4-{[7-{[3-(diethylamino)propyl] oxy}-6-(methyloxy) quinazolin-4-yl]oxy}-3- fluorophenyl)-N'-(4- fluorophenyl) cyclopropane-1,1-dicarboxamide; for modulating protein kinase enzymatic activity for modulating cell activities such as proliferation, differentiation, programmed cell death EXELIXIS, INC. (US) 2009-08-25 — — US disclosed
US-20090170896-A1 c-Met modulators and methods of use EXELIXIS, INC. (US) 2009-07-02 — — US disclosed
US-20090105299-A1 c-MET MODULATORS AND METHODS OF USE EXELIXIS, INC (US) 2009-04-23 — — US disclosed
EP-1673085-A4 C-MET MODULATORS AND METHODS OF USE EXELIXIS INC (US) 2008-12-10 — — EP disclosed
US-20070225307-A1 C-MET MODULATORS AND METHOD OF USE EXELIXIS, INC. (US) 2007-09-27 — — US disclosed
US-20070054928-A1 c-Met modulators and methods of use EXELIXIS, INC. (US) 2007-03-08 — — US disclosed
EP-1673085-A2 C-MET MODULATORS AND METHODS OF USE Exelixis, Inc. (US) 2006-06-28 — — EP disclosed
WO-2005030140-A2 C-MET MODULATORS AND METHODS OF USE EXELIXIS, INC. (US) 2005-04-07 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200331860-A1 C-Met Modulators and Methods of Use FLT4, FLT1, MET EGFR 124/4885KDR 4/4885FGFR1 270/4885
US-20070054928-A1 c-Met modulators and methods of use FLT4, FLT1, MET EGFR 124/4885KDR 4/4885FGFR1 270/4885
US-20140155396-A1 C-Met Modulators and Method of Use FLT4, MET, FLT1 EGFR 181/4885KDR 5/4885FGFR1 202/4885
US-20170355678-A1 C-Met Modulators and Methods of Use FLT4, FLT1, MET EGFR 124/4885KDR 4/4885FGFR1 270/4885
US-20210253530-A9 C-MET MODULATORS AND METHODS OF USE FLT4, FLT1, MET EGFR 124/4885KDR 4/4885FGFR1 270/4885
US-20090170896-A1 c-Met modulators and methods of use FLT4, MET, FLT1 EGFR 166/4885KDR 5/4885FGFR1 202/4885
US-20070225307-A1 C-MET MODULATORS AND METHOD OF USE FLT4, MET, FLT1 EGFR 181/4885KDR 5/4885FGFR1 202/4885
US-20160185725-A1 c-Met Modulators and Method of Use FLT4, MET, FLT1 EGFR 181/4885KDR 5/4885FGFR1 202/4885
US-11124482-B2 C-met modulators and methods of use FLT4, FLT1, MET EGFR 124/4885KDR 4/4885FGFR1 270/4885
US-20090105299-A1 c-MET MODULATORS AND METHODS OF USE FLT4, MET, FLT1 EGFR 166/4885KDR 5/4885FGFR1 202/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.